Dublin, Ireland, 1st February 2007 - AGI Therapeutics plc (“AGI” or the “Company”) (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces preliminary results of Phase II studies for mecamylamine (AGI-004, for functional diarrhoea) and arbaclofen (AGI-006 for functional dyspepsia). The results of these studies follow the reporting last year of positive results for other AGI products in development.
